NSE / BSEHealthcare
β‚Ή1398.05-9.45-0.67%
P/E59.8Mkt Capβ‚Ή31.40 K CrEV/EBITDA37.3

Global Health Limited

P/E59.8Mkt Capβ‚Ή31.40 K CrEV/EBITDA37.3
Company Profile

Global Health Limited, together with its subsidiaries, provides healthcare services in India. The company offers treatments in the areas of digestive and hepatobiliary sciences, cardiac and cancer care, neurosciences, gastrosciences, orthopaedics, renal care, liver transplant, lung transplant, bone marrow transplant, chest surgery, gynaecology and gynaeoncology, paediatric care, obstetrics, emergency, ENT, head and neck surgery, internal medicine, respiratory and sleep medicine, peripheral vascular and endovascular sciences, endocrinology and diabetes, rheumatology and immunology, radiology and imaging, ophthalmology, critical care, dermatology, dentistry, and dietetics and nutrition, as well as plastic, aesthetic, and reconstructive surgery. It also provides second opinion, lab tests and diagnostics, homecare and elder care services, telemedicine and air ambulance services, and e-ICU services, and health plans checkup. In addition, the company is involved in trading of pharmacy and other medical consumables; and medical and healthcare education activities. The company operates a network of hospitals under the Medanta brand. Global Health Limited was incorporated in 2004 and is based in Gurugram, India.

Valuation

Market Cap
β‚Ή0.00
β€”
Current Price
β‚Ή0
β€”as of 28 Jul 2026
P/E Ratio
0.0x
β€”
P/B Ratio
0.0x
β€”
EV / EBITDA
0.0x
β€”
EV / Sales
0.0x
β€”
52W High
β‚Ή0
β€”
52W Low
β‚Ή0
β€”
Shares Out
0.00 Cr
β€”

Profitability

Operating Margin
0.0%
β€”
Net Profit Margin
0.0%
β€”
EBITDA Margin
0.0%
β€”

Returns

ROE
0.0%
β€”
ROCE
0.0%
β€”
ROIC %
β€”
β€”
ROA
0.0%
β€”
Dividend Payout
0.0%
β€”

Solvency

Current Ratio
0.0x
β€”
Debt / Equity
0.0x
β€”
Debt / Assets
0.0x
β€”
CFO / Net Profit
0.0x
β€”
Interest Coverage
0.0x
β€”

AI Summary

Indian Stock

Sign up free to view AI insights

Get Started

Rule-based from financial data. Not advice.

Price Historyβ–² 3.42% over 1Y
Monthly Returns

Historically, Feb has averaged the highest return (+13.5%); Sep the lowest (-4.4%).

Average from:
YearJanFebMarAprMayJunJulAugSepOctNovDec
2026-11.0%Negative MonthJan 2026: -11.04%+8.1%Positive MonthFeb 2026: +8.14%-15.7%Negative MonthMar 2026: -15.71%+16.2%Positive MonthApr 2026: +16.21%+10.8%Positive MonthMay 2026: +10.81%+6.1%Positive MonthJun 2026: +6.14%+6.3%*Positive MonthJul 2026: +6.35%β€”β€”β€”β€”β€”
2025-3.3%Negative MonthJan 2025: -3.33%+10.2%Positive MonthFeb 2025: +10.20%+4.2%Positive MonthMar 2025: +4.21%+0.0%Neutral MonthApr 2025: +0.02%-0.9%Neutral MonthMay 2025: -0.91%-4.1%Negative MonthJun 2025: -4.05%+15.0%Positive MonthJul 2025: +15.04%+4.9%Positive MonthAug 2025: +4.86%-4.4%Negative MonthSep 2025: -4.45%+0.0%Neutral MonthOct 2025: +0.04%-5.2%Negative MonthNov 2025: -5.20%-4.8%Negative MonthDec 2025: -4.79%
2024+19.7%Positive MonthJan 2024: +19.73%+18.9%Positive MonthFeb 2024: +18.86%-3.0%Negative MonthMar 2024: -2.98%+9.2%Positive MonthApr 2024: +9.16%-17.4%Negative MonthMay 2024: -17.44%+9.5%Positive MonthJun 2024: +9.54%-5.1%Negative MonthJul 2024: -5.09%-8.6%Negative MonthAug 2024: -8.58%-9.4%Negative MonthSep 2024: -9.38%+7.6%Positive MonthOct 2024: +7.61%-2.7%Negative MonthNov 2024: -2.75%+0.4%Neutral MonthDec 2024: +0.37%
2023-4.9%Negative MonthJan 2023: -4.92%+16.9%Positive MonthFeb 2023: +16.91%+1.1%Neutral MonthMar 2023: +1.12%-2.2%Negative MonthApr 2023: -2.17%+15.3%Positive MonthMay 2023: +15.26%+11.2%Positive MonthJun 2023: +11.18%+6.8%Positive MonthJul 2023: +6.75%+0.9%Neutral MonthAug 2023: +0.85%+0.7%Neutral MonthSep 2023: +0.75%+9.7%Positive MonthOct 2023: +9.65%+22.3%Positive MonthNov 2023: +22.34%-0.1%Neutral MonthDec 2023: -0.11%
2022β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”+1.1%Neutral MonthDec 2022: +1.11%
AvgΒ±SD+0.1%Β±11.7%+13.5%Β±4.5%-3.3%Β±7.6%+5.8%Β±7.4%+1.9%Β±12.6%+5.7%Β±5.9%+5.8%Β±7.2%-1.0%Β±5.6%-4.4%Β±4.1%+5.8%Β±4.1%+4.8%Β±12.4%-0.9%Β±2.3%
* Current month β€” value will change until month-end.

Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation β€” the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.

Seasonal Tendency

This aggregates every month by calendar position β€” all Januaries together, all Februaries together, and so on β€” to show whether a given month has leaned positive or negative historically. β€˜Simple’ counts each month as +1 or βˆ’1. β€˜Weighted’ gives larger moves more influence: +2 above +10%, βˆ’2 below βˆ’10%. With only 5 years of history for this asset, each month’s score reflects a small number of observations β€” read it as a historical tendency, not a reliable seasonal pattern.

Historical Trend

This tracks a running tally across the asset’s full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.

Year-to-Date ROI
Average from:
SD Γ—
Latest: 1.179x (2026)

Year-to-date return is calculated by dividing each day’s closing price by the price on January 1st of that year (or the asset’s first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen β€” at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in β€œAverage from”, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.

Historical Performance

Revenue, profitability, and cash flow trends (β‚Ή Crores)

Revenue (10Y)

Operating Income (10Y)

Net Profit (10Y)

Operating Margin % (10Y)

Dividend Payout % (10Y)

Free Cash Flow (10Y)

Growth Summary

Latest fiscal year: Mar 2025

Revenueβ‚Ή3.20 K Crβ–² 7.7%
EBITDA Growthβ€”
Net Profitβ‚Ή462.00 Crβ–Ό 4.9%
Cash from Ops (CFO)β€”
Free Cash Flow (FCF)β€”β–Ό 39.5%
Revenue CAGR 5Y15.1%
EBITDA CAGR 5Y26.4%
Net Profit CAGR 5Y36.4%
NP Growth 1Y-4.9%

Historical Growth

Year-by-year revenue, profitability, and cash flow (β‚Ή Crores, last 10 years)

YearRevenueOp. IncomeNet ProfitCFOFCFROERev Growth 1YNP Growth 1Y
Mar 2025β‚Ή3.20 K Crβ€”β‚Ή462.00 Crβ€”β€”13.2%7.7%-4.9%
Mar 2024β‚Ή2.98 K Crβ€”β‚Ή486.00 Crβ€”β€”16.0%50.7%84.8%
Mar 2023β‚Ή1.97 K Crβ€”β‚Ή263.00 Crβ€”β€”10.6%11.8%20.1%
Mar 2022β‚Ή1.76 K Crβ€”β‚Ή219.00 Crβ€”β€”12.6%43.8%284.2%
Mar 2021β‚Ή1.23 K Crβ€”β‚Ή57.00 Crβ€”β€”3.8%-16.6%-44.7%
Mar 2020β‚Ή1.47 K Crβ€”β‚Ή103.00 Crβ€”β€”7.4%2.2%63.5%
Mar 2019β‚Ή1.44 K Crβ€”β‚Ή63.00 Crβ€”β€”4.9%7.3%70.3%
Mar 2018β‚Ή1.34 K Crβ€”β‚Ή37.00 Crβ€”β€”3.1%5.2%-31.5%
Mar 2017β‚Ή1.28 K Crβ€”β‚Ή54.00 Crβ€”β€”4.8%β€”β€”

Financial Statements

Income statement, balance sheet, and cash flow (β‚Ή Crores, as reported)

Consolidated Figures in USD Millions.

Unnamed: 0Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Revenue / Net Sales1,2771,3431,4411,4721,2271,7651,9742,9753,2043,424
Total Expenses1,1581,2181,2971,2531,0541,3841,5512,2222,4322,640
EBIT / Operating Profit119125144219173381423753772784
OPM %9%9%10%15%14%22%21%25%24%23%
Other Income67496443283547914177
Finance Costs19242133293332514130
Depreciation & Amortisation77869199888786134150146
Profit Before Tax89649713184296352659623684
Tax %39%42%35%22%32%26%25%26%26%-
Net Profit / PAT54376310357219263486462517
EPS (β‚Ή)11.217.7012.8120.8211.558.649.8218.1117.1819.24
Dividend Payout %0%0%0%0%0%0%0%0%0%-

Peer Comparison

Healthcare sector peers, ranked by market cap

CompanyMarket CapRevenueP/EP/BEV/EBITDARev G 1Y
Global Health Limitedthis co.β‚Ή31.40 K Crβ‚Ή3.20 K Cr59.808.2837.317.7%
Sun Pharmaceutical Industries Ltd.β‚Ή4.15 L Crβ‚Ή23.00 K Cr88.7017.4372.3013.5%
Divi's Laboratories Ltd.β‚Ή1.71 L Crβ‚Ή9.20 K Cr67.9011.1367.2120.0%
Torrent Pharmaceuticals Ltd.β‚Ή1.33 L Crβ‚Ή9.68 K Cr62.5015.7645.6413.5%
Cipla Ltd.β‚Ή1.17 L Crβ‚Ή19.05 K Cr22.503.5119.3314.9%
Apollo Hospitals Enterprises Ltd.β‚Ή1.05 L Crβ‚Ή8.20 K Cr75.0011.2854.4412.8%
Max Healthcare Institute Limitedβ‚Ή1.00 L Crβ‚Ή2.66 K Cr144.0011.7696.8413.8%
Industry Averageβ€”β‚Ή3.29 K Cr98.638.1165.5020.2%

Learn while you research

Hand-picked academy chapters to deepen your understanding of Global Health Limited and the metrics that matter.

Browse the full Equiscale Academy